Do we really need five TNF antagonists? Or more insight into the use of existing options?

Eric M. Ruderman

doi:10.1093/rheumatology/keq016

Do we really need five TNF antagonists? Or more insight into the use of existing options?

Eric M. Ruderman^*

^*Corresponding author for this work

Medicine, Rheumatology Division

Research output: Contribution to journal › Editorial › peer-review

1 Scopus citations

Original language	English (US)
Article number	keq016
Pages (from-to)	1028-1029
Number of pages	2
Journal	Rheumatology
Volume	49
Issue number	6
DOIs	https://doi.org/10.1093/rheumatology/keq016
State	Published - Feb 19 2010

Funding

Disclosure statement: E.M.R. has received consulting fees from Abbott Immunology, Amgen/Wyeth and UCB. He has received research funding from Abbott Immunology and Centocor.

ASJC Scopus subject areas

Pharmacology (medical)
Rheumatology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/rheumatology/keq016

Cite this

@article{7a760f7a0642476183ea64abf2f36596,

title = "Do we really need five TNF antagonists? Or more insight into the use of existing options?",

author = "Ruderman, \{Eric M.\}",

note = "Funding Information: Disclosure statement: E.M.R. has received consulting fees from Abbott Immunology, Amgen/Wyeth and UCB. He has received research funding from Abbott Immunology and Centocor.",

year = "2010",

month = feb,

day = "19",

doi = "10.1093/rheumatology/keq016",

language = "English (US)",

volume = "49",

pages = "1028--1029",

journal = "Rheumatology",

issn = "1462-0324",